Fulgent Genetics, Inc. (FLGT) Q4 FY25 Earnings Call

2026 revenue growth depends on acquisitions and recovery from a $59 million largest-customer revenue loss [25][41].

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-27
Length50 minutes
EPS$-0.11
EPS consensus$-0.27
Revenue$84.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26 · Q1 FY26

All FLGT earnings · Back to FLGT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.